1
BIOD 351 / BIOD351 Pharmacology Module 1
Exam Actual Exam 2026/2027 – Complete Exam-
Style Questions with Detailed Rationales | 100%
Verified – Pass Guaranteed – A+ Graded
Section 1: Pharmacokinetics
Q1: A patient is prescribed a weak acid drug for a peptic ulcer. Understanding the principles of
absorption, in which area of the gastrointestinal tract will this drug be absorbed most efficiently?
A. Stomach
B. Duodenum
C. Jejunum
D. Ileum
Correct Answer: A
Rationale: Weak acids remain predominantly in their non-ionized, lipid-soluble state in an acidic
environment like the stomach. Since non-ionized drugs cross lipid membranes more easily, weak
acids are best absorbed in the stomach.
Q2: A nurse is preparing to administer nitroglycerin sublingually rather than orally. What is the
primary pharmacokinetic rationale for this route of administration?
A. The sublingual route has a slower onset of action.
B. The sublingual route avoids the first-pass effect. [CORRECT]
C. The sublingual route allows for hepatic metabolism.
D. The sublingual route provides a prolonged duration of action.
Correct Answer: B
Rationale: Drugs administered sublingually enter the systemic circulation directly via the highly
vascularized sublingual mucosa, bypassing the portal circulation and the liver's first-pass
metabolism, resulting in a rapid onset of action.
,2
Q3: A patient is started on a new medication with a half-life of 12 hours. Approximately how
long will it take for this drug to reach steady-state concentration if it is administered on a regular
schedule?
A. 12 hours
B. 24 hours
C. 48 to 60 hours
D. 5 to 7 days
Correct Answer: C
Rationale: It takes approximately 4 to 5 half-lives for a drug to reach steady-state concentration
in the body. Since the half-life is 12 hours, 4 to 5 half-lives equals 48 to 60 hours.
Q4: A patient with cirrhosis is experiencing a decrease in the metabolism of certain medications.
Which phase of biotransformation is most likely impaired in this patient?
A. Phase I oxidation via the cytochrome P450 system
B. Phase II conjugation via glucuronidation [CORRECT]
C. Phase I reduction
D. Phase II acetylation
Correct Answer: B
Rationale: While cirrhosis can impair both phases, severe liver disease particularly impairs Phase
II reactions like glucuronidation because these processes require high-energy cofactors (like
UDPGA) that are depleted in failing hepatocytes.
Q5: A highly protein-bound drug (99%) is administered to a patient. If a second drug is added
that competes for the same binding sites, what is the expected pharmacokinetic outcome?
A. A decrease in the free (active) drug concentration
B. An increase in the free (active) drug concentration [CORRECT]
C. A decrease in the volume of distribution
D. A rapid increase in hepatic metabolism
Correct Answer: B
,3
Rationale: When a highly protein-bound drug is displaced from its binding sites by a competitor,
the concentration of free, pharmacologically active drug increases temporarily, which can lead to
toxic effects until the free drug is metabolized and excreted.
Q6: Penicillin is actively secreted into the renal tubules. If a healthcare provider wants to prolong
the half-life of penicillin, which agent might be co-administered to block this secretion?
A. Probenecid
B. Furosemide
C. Mannitol
D. Spironolactone
Correct Answer: A
Rationale: Probenecid is a weak organic acid that competes with penicillin for the same organic
anion transporter (OAT) in the renal proximal tubule. By blocking tubular secretion, probenecid
decreases the renal clearance and prolongs the half-life of penicillin.
Q7: A drug has a bioavailability (F) of 0.4. If a patient takes a 100 mg oral dose, what is the
actual amount of the drug that reaches the systemic circulation?
A. 40 mg
B. 60 mg
C. 100 mg
D. 140 mg
Correct Answer: A
Rationale: Bioavailability (F) is the fraction of the administered dose that reaches the systemic
circulation unchanged. A bioavailability of 0.4 means 40% of the dose reaches systemic
circulation; 40% of 100 mg is 40 mg.
Q8: A lipid-soluble drug that readily crosses the blood-brain barrier is administered. Which
parameter best explains why this drug concentrates extensively in the adipose tissue of an obese
patient?
A. Low lipid solubility
, 4
B. High plasma protein binding
C. Large volume of distribution (Vd) [CORRECT]
D. High hepatic clearance
Correct Answer: C
Rationale: Lipophilic drugs distribute widely into adipose tissue and total body water, resulting
in a large volume of distribution (Vd). This means the drug concentration in the plasma is
relatively low compared to the total amount of drug in the body.
Q9: A patient is taking a drug that is metabolized by CYP3A4. They begin drinking grapefruit
juice daily. What is the expected pharmacokinetic effect?
A. Increased metabolism of the drug
B. Decreased bioavailability of the drug
C. Inhibition of CYP3A4, leading to increased drug levels [CORRECT]
D. Induction of CYP3A4, leading to decreased drug levels
Correct Answer: C
Rationale: Grapefruit juice contains furanocoumarins, which are irreversible inhibitors of
intestinal CYP3A4. This inhibition decreases the pre-systemic metabolism of the drug,
increasing its bioavailability and plasma concentration.
Q10: A patient is prescribed a drug with a half-life of 4 hours for a chronic condition. Which
dosing frequency is most appropriate to avoid large peaks and troughs in drug concentration?
A. Once daily
B. Every 8 hours
C. Every 4 to 6 hours [CORRECT]
D. Once weekly
Correct Answer: C
Rationale: To maintain relatively stable plasma concentrations and minimize toxicity from high
peaks or therapeutic failure from low troughs, a drug should generally be administered at an
interval roughly equal to or less than its half-life (4 to 6 hours).
BIOD 351 / BIOD351 Pharmacology Module 1
Exam Actual Exam 2026/2027 – Complete Exam-
Style Questions with Detailed Rationales | 100%
Verified – Pass Guaranteed – A+ Graded
Section 1: Pharmacokinetics
Q1: A patient is prescribed a weak acid drug for a peptic ulcer. Understanding the principles of
absorption, in which area of the gastrointestinal tract will this drug be absorbed most efficiently?
A. Stomach
B. Duodenum
C. Jejunum
D. Ileum
Correct Answer: A
Rationale: Weak acids remain predominantly in their non-ionized, lipid-soluble state in an acidic
environment like the stomach. Since non-ionized drugs cross lipid membranes more easily, weak
acids are best absorbed in the stomach.
Q2: A nurse is preparing to administer nitroglycerin sublingually rather than orally. What is the
primary pharmacokinetic rationale for this route of administration?
A. The sublingual route has a slower onset of action.
B. The sublingual route avoids the first-pass effect. [CORRECT]
C. The sublingual route allows for hepatic metabolism.
D. The sublingual route provides a prolonged duration of action.
Correct Answer: B
Rationale: Drugs administered sublingually enter the systemic circulation directly via the highly
vascularized sublingual mucosa, bypassing the portal circulation and the liver's first-pass
metabolism, resulting in a rapid onset of action.
,2
Q3: A patient is started on a new medication with a half-life of 12 hours. Approximately how
long will it take for this drug to reach steady-state concentration if it is administered on a regular
schedule?
A. 12 hours
B. 24 hours
C. 48 to 60 hours
D. 5 to 7 days
Correct Answer: C
Rationale: It takes approximately 4 to 5 half-lives for a drug to reach steady-state concentration
in the body. Since the half-life is 12 hours, 4 to 5 half-lives equals 48 to 60 hours.
Q4: A patient with cirrhosis is experiencing a decrease in the metabolism of certain medications.
Which phase of biotransformation is most likely impaired in this patient?
A. Phase I oxidation via the cytochrome P450 system
B. Phase II conjugation via glucuronidation [CORRECT]
C. Phase I reduction
D. Phase II acetylation
Correct Answer: B
Rationale: While cirrhosis can impair both phases, severe liver disease particularly impairs Phase
II reactions like glucuronidation because these processes require high-energy cofactors (like
UDPGA) that are depleted in failing hepatocytes.
Q5: A highly protein-bound drug (99%) is administered to a patient. If a second drug is added
that competes for the same binding sites, what is the expected pharmacokinetic outcome?
A. A decrease in the free (active) drug concentration
B. An increase in the free (active) drug concentration [CORRECT]
C. A decrease in the volume of distribution
D. A rapid increase in hepatic metabolism
Correct Answer: B
,3
Rationale: When a highly protein-bound drug is displaced from its binding sites by a competitor,
the concentration of free, pharmacologically active drug increases temporarily, which can lead to
toxic effects until the free drug is metabolized and excreted.
Q6: Penicillin is actively secreted into the renal tubules. If a healthcare provider wants to prolong
the half-life of penicillin, which agent might be co-administered to block this secretion?
A. Probenecid
B. Furosemide
C. Mannitol
D. Spironolactone
Correct Answer: A
Rationale: Probenecid is a weak organic acid that competes with penicillin for the same organic
anion transporter (OAT) in the renal proximal tubule. By blocking tubular secretion, probenecid
decreases the renal clearance and prolongs the half-life of penicillin.
Q7: A drug has a bioavailability (F) of 0.4. If a patient takes a 100 mg oral dose, what is the
actual amount of the drug that reaches the systemic circulation?
A. 40 mg
B. 60 mg
C. 100 mg
D. 140 mg
Correct Answer: A
Rationale: Bioavailability (F) is the fraction of the administered dose that reaches the systemic
circulation unchanged. A bioavailability of 0.4 means 40% of the dose reaches systemic
circulation; 40% of 100 mg is 40 mg.
Q8: A lipid-soluble drug that readily crosses the blood-brain barrier is administered. Which
parameter best explains why this drug concentrates extensively in the adipose tissue of an obese
patient?
A. Low lipid solubility
, 4
B. High plasma protein binding
C. Large volume of distribution (Vd) [CORRECT]
D. High hepatic clearance
Correct Answer: C
Rationale: Lipophilic drugs distribute widely into adipose tissue and total body water, resulting
in a large volume of distribution (Vd). This means the drug concentration in the plasma is
relatively low compared to the total amount of drug in the body.
Q9: A patient is taking a drug that is metabolized by CYP3A4. They begin drinking grapefruit
juice daily. What is the expected pharmacokinetic effect?
A. Increased metabolism of the drug
B. Decreased bioavailability of the drug
C. Inhibition of CYP3A4, leading to increased drug levels [CORRECT]
D. Induction of CYP3A4, leading to decreased drug levels
Correct Answer: C
Rationale: Grapefruit juice contains furanocoumarins, which are irreversible inhibitors of
intestinal CYP3A4. This inhibition decreases the pre-systemic metabolism of the drug,
increasing its bioavailability and plasma concentration.
Q10: A patient is prescribed a drug with a half-life of 4 hours for a chronic condition. Which
dosing frequency is most appropriate to avoid large peaks and troughs in drug concentration?
A. Once daily
B. Every 8 hours
C. Every 4 to 6 hours [CORRECT]
D. Once weekly
Correct Answer: C
Rationale: To maintain relatively stable plasma concentrations and minimize toxicity from high
peaks or therapeutic failure from low troughs, a drug should generally be administered at an
interval roughly equal to or less than its half-life (4 to 6 hours).
